Skip to main content
SpringerLink
Log in

Population Pharmacokinetics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran, in Atrial Fibrillation Patients Receiving Long-Term Anticoagulation Therapy

  • Original Research Article
  • Published:
Clinical Pharmacokinetics Aims and scope Submit manuscript

Abstract

Background

Ximelagatran is an oral direct thrombin inhibitor for the prevention of thromboembolic disease. After oral administration, ximelagatran is rapidly absorbed and bioconverted to its active form, melagatran.

Objective

To characterise the pharmacokinetics of melagatran in patients with nonvalvular atrial fibrillation (NVAF) receiving long-term treatment for prevention of stroke and systemic embolic events.

Methods

A population pharmacokinetic model was developed based on data from three phase II studies (1177 plasma concentration observations in 167 patients, treated for up to 18 months) and confirmed by including data from two phase III studies (8702 plasma concentration observations in 3188 patients, treated for up to 24 months). The impact of individualised dosing on pharmacokinetic variability was evaluated by simulations of melagatran concentrations based on the pharmacokinetic model.

Results

Melagatran pharmacokinetics were consistent across the studied doses and duration of treatment, and were described by a one-compartment model with first-order absorption and elimination. Clearance of melagatran was correlated to creatinine clearance, which was the most important predictor of melagatran exposure (explained 54% of interpatient variance in clearance). Total variability (coefficient of variation) in exposure was 45%; intraindividual variability in exposure was 23%. Concomitant medication with the most common long-term used drugs in the study population had no relevant influence on melagatran pharmacokinetics. Simulations suggested that dose adjustment based on renal function or trough plasma concentration had a minor effect on overall pharmacokinetic variability and the number of patients with high melagatran exposure.

Conclusion

The pharmacokinetics of melagatran in NVAF patients were predictable, and consistent with results from previously studied patient populations. Dose individualisation was predicted to have a low impact on pharmacokinetic variability, supporting the use of a fixed-dose regimen of ximelagatran for long-term anticoagulant therapy in the majority of NVAF patients.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Table I
Fig. 1
Fig. 2
Table II
Fig. 3
Fig. 4
Table III
Table IV
Fig. 5

Similar content being viewed by others

References

  1. Gustafsson D, Nyström J, Carlsson S, et al. The direct thrombin inhibitor melagatran and its oral prodrug H 376/95: intestinal absorption properties, biochemical and pharmacodynamic effects. Thromb Res 2001; 101: 171–81

    Article  PubMed  CAS  Google Scholar 

  2. Eriksson UG, Bredberg U, Hoffmann KJ, et al. Absorption, distribution, metabolism, and excretion of ximelagatran, an oral direct thrombin inhibitor, in rats, dogs, and humans. Drug Metab Dispos 2003; 31: 294–305

    Article  PubMed  CAS  Google Scholar 

  3. Gustafsson D, Antonsson T, Bylund R, et al. Effects of melagatran, a new low-molecular-weight thrombin inhibitor, on thrombin and fibrinolytic enzymes. Thromb Haemost 1998; 79: 110–8

    PubMed  CAS  Google Scholar 

  4. Eriksson UG, Bredberg U, Gislen K, et al. Pharmacokinetics and pharmacodynamics of ximelagatran, a novel oral direct thrombin inhibitor, in young healthy male subjects. Eur J Clin Pharmacol 2003; 59: 35–43

    PubMed  CAS  Google Scholar 

  5. Johansson LC, Frison L, Logren U, et al. Influence of age on the pharmacokinetics and pharmacodynamics of ximelagatran, an oral direct thrombin inhibitor. Clin Pharmacokinet 2003; 42: 381–92

    Article  PubMed  CAS  Google Scholar 

  6. Bredberg E, Andersson TB, Frison L, et al. Ximelagatran, an oral direct thrombin inhibitor, has a low potential for cytochrome P450-mediated drug-drug interactions. Clin Pharmacokinet 2003; 42: 765–77

    Article  PubMed  CAS  Google Scholar 

  7. Heit JA, Colwell CW, Francis CW, et al. Comparison of the oral direct thrombin inhibitor ximelagatran with enoxaparin as prophylaxis against venous thromboembolism after total knee replacement: a phase 2 dose-finding study. Arch Intern Med 2001; 161: 2215–21

    Article  PubMed  CAS  Google Scholar 

  8. Eriksson BI, Bergqvist D, Kalebo P, et al. Ximelagatran and melagatran compared with dalteparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO II randomised trial. Lancet 2002; 360: 1441–7

    Article  PubMed  CAS  Google Scholar 

  9. Eriksson BI, Agnelli G, Cohen AT, et al. The direct thrombin inhibitor melagatran followed by oral ximelagatran compared with enoxaparin for the prevention of venous thromboembolism after total hip or knee replacement: the EXPRESS study. J Thromb Haemost 2003; 1: 2490–6

    Article  PubMed  CAS  Google Scholar 

  10. Eriksson BI, Agnelli G, Cohen AT, et al., the METHRO III study group. Direct thrombin inhibitor melagatran followed by oral ximelagatran in comparison with enoxaparin for prevention of venous thromboembolism after total hip or knee replacement: the METHRO III study. Thromb Haemost 2003; 89: 288–96

    PubMed  CAS  Google Scholar 

  11. Dahl OE, Eriksson BI, Agnelli G, et al. The effects of timing of first dose and risk factors for thromboembolism and bleeding complications on the efficacy and safety of postoperative melagatran/ximelagatran for the prevention of venous thromboembolism following major elective orthopaedic surgery. Clin Drug Invest 2005; 25: 65–77

    Article  CAS  Google Scholar 

  12. Eriksson H, Wahlander K, Gustafsson D, et al. A randomized, controlled, dose-guiding study of the oral direct thrombin inhibitor ximelagatran compared with standard therapy for the treatment of acute deep vein thrombosis: THRIVE I. J Thromb Haemost 2003; 1: 41–7

    Article  PubMed  CAS  Google Scholar 

  13. Petersen P, Grind M, Adler J. Ximelagatran versus warfarin for stroke prevention in patients with nonvalvular atrial fibrillation. SPORTIF II: a dose-guiding, tolerability, and safety study. J Am Coll Cardiol 2003; 41: 1445–51

    Article  PubMed  CAS  Google Scholar 

  14. Olsson SB, Petersen P, SPORTIF II and IV investigators. Ximelagatran: a long-term oral direct thrombin inhibitor for stroke and systemic embolism prevention in nonvalvular atrial fibrillation patients [abstract]. Eur Heart J 2002; Suppl. 4 Suppl: 239

    Google Scholar 

  15. Executive Steering Committee, SPORTIF III Investigators. Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation (SPORTIF III): a randomized trial. Lancet 2003; 362: 1691–8

    Article  Google Scholar 

  16. SPORTIF Executive Steering Committee, SPORTIF V Investigators. Ximelagatran vs warfarin for stroke prevention in patients with nonvalvular atrial fibrillation: a randomized trial. JAMA 2005; 293: 690–8

    Article  Google Scholar 

  17. Albers GW, Dalen JE, Laupacis A, et al. Antithrombotic therapy in atrial fibrillation. Chest 2001; 119(1): 194S–206S

    Article  PubMed  CAS  Google Scholar 

  18. Wolf PA, Abbott RD, Kannel WB. Atrial fibrillation as an independent risk factor for stroke: the Framingham Study. Stroke 1991; 22: 983–8

    Article  PubMed  CAS  Google Scholar 

  19. Fuster V, Ryden LE, Asinger RW, et al. ACC/AHA/ESC guidelines for the management of patients with atrial fibrillation: executive summary a report of the American College of Cardiology/American Heart Association Task Force on practice guidelines and the European Society of Cardiology Committee for practice guidelines and policy conferences (committee to develop guidelines for the management of patients with atrial fibrillation) developed in collaboration with the north American Society of Pacing and Electrophysiology. Circulation 2001; 104: 2118–50

    PubMed  CAS  Google Scholar 

  20. Hirsh J, Dalen JE, Anderson DR, et al. Oral anticoagulants: mechanism of action, clinical effectiveness, and optimal therapeutic range. Chest 2001; 119(1): 8S–21S

    Article  PubMed  CAS  Google Scholar 

  21. Eriksson UG, Mandema JW, Karlsson MO, et al. Pharmacokinetics of melagatran and the effect on ex vivo coagulation time in orthopaedic surgery patients receiving subcutaneous melagatran and oral ximelagatran: a population model analysis. Clin Pharmacokinet 2003; 42: 687–701

    Article  PubMed  CAS  Google Scholar 

  22. Wolzt M, Wollbratt M, Svensson M, et al. Consistent pharmacokinetics of the oral direct thrombin inhibitor ximelagatran in patients with nonvalvular atrial fibrillation and in healthy subjects. Eur J Clin Pharmacol 2003; 59: 537–43

    Article  PubMed  CAS  Google Scholar 

  23. Halperin JL. Ximelagatran compared with warfarin for prevention of thromboembolism in patients with nonvalvular atrial fibrillation: rationale, objectives, and design of a pair of clinical studies and baseline patient characteristics (SPORTIF III and V). Am Heart J 2003; 146: 431–8

    Article  PubMed  CAS  Google Scholar 

  24. Larsson M, Logren U, Ahnoff M, et al. Determination of melagatran, a novel, direct thrombin inhibitor, in human plasma and urine by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2002; 766: 47–55

    Article  PubMed  CAS  Google Scholar 

  25. Larsson M, Ahnoff M, Abrahamsson A, et al. Determination of ximelagatran, an oral direct thrombin inhibitor, its active metabolite melagatran, and the intermediate metabolites, in biological samples by liquid chromatography-mass spectrometry. J Chromatogr B Analyt Technol Biomed Life Sci 2003; 783: 335–47

    Article  PubMed  CAS  Google Scholar 

  26. Cockroft DW, Gault MH. Prediction of creatinine clearance from serum creatinine. Nephron 1976; 16: 31–41

    Article  Google Scholar 

  27. Beal SL, Sheiner LB. NONMEM user’s guides (I-VIII). Hanover (MD): GloboMax, 1989-1998

  28. Jonsson EN, Karlsson MO. Xpose: an S-PLUS based population pharmacokinetic/pharmacodynamic model building aid for NONMEM. Comput Methods Programs Biomed 1999; 58: 51–64

    Article  PubMed  CAS  Google Scholar 

  29. Pharsight Trial Simulator User’s Guide program. Version 2.1. Mountain View (CA): Pharsight Corporation, 2000

  30. Cullberg M, Eriksson H, Eriksson UG, et al. Pharmacokinetics of melagatran after oral dosing with ximelagatran, a direct thrombin inhibitor, in patients with acute venous thromboembolism [abstract]. Clin Pharmacol Ther 2002; 71: 61

    Google Scholar 

  31. Levey AS, Perrone RD, Madias NE. Serum creatinine and renal function. Annu Rev Med 1988; 39: 465–90

    Article  PubMed  CAS  Google Scholar 

  32. Food and Drug Administration. In vivo drug metabolism/drug interaction studies: study design, data analysis, and recommendations for dosing and labeling: guidance for industry. Rockville (MD): 1999

  33. Teng R, Sarich TC, Eriksson UG, et al. A pharmacokinetic study of the combined administration of amiodarone and ximelagatran, an oral direct thrombin inhibitor. J Clin Pharmacol 2004; 44: 1063–71

    Article  PubMed  CAS  Google Scholar 

  34. Sarich TC, Schutzer KM, Dorani H, et al. No pharmacokinetic or pharmacodynamic interaction between atorvastatin and the oral direct thrombin inhibitor ximelagatran. J Clin Pharmacol 2004; 44: 928–34

    Article  PubMed  CAS  Google Scholar 

  35. Sarich TC, Schutzer KM, Wollbratt M, et al. No pharmacokinetic or pharmacodynamic interaction between digoxin and the oral direct thrombin inhibitor ximelagatran in healthy volunteers. J Clin Pharmacol 2004; 44: 935–41

    Article  PubMed  CAS  Google Scholar 

Download references

Acknowledgements

The authors wish to thank Ulrika Logren and colleagues at DMPK and Bioanalytical Chemistry, AstraZeneca R&D Mölndal, for performing the bioanalysis of pharmacokinetic plasma samples.

Sofie Bååthe, Bengt Hamrén, Maria Wollbratt, Margaretha Grind and Ulf G. Eriksson are employees of AstraZeneca. Mats O. Karlsson received research funding from AstraZeneca.

Author information

Authors and Affiliations

  1. AstraZeneca R&D Mölndal, S-431 83, Mölndal, Sweden

    Sofie Bååthe, Bengt Hamrén, Maria Wollbratt & Ulf G. Eriksson

  2. Department of Pharmaceutical Biosciences, Uppsala University, Uppsala, Sweden

    Mats O. Karlsson

  3. AstraZeneca R&D Charnwood, Loughborough, United Kingdom

    Margaretha Grind

Authors
  1. Sofie Bååthe
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Bengt Hamrén
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. Mats O. Karlsson
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. Maria Wollbratt
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. Margaretha Grind
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. Ulf G. Eriksson
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Sofie Bååthe.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Bååthe, S., Hamrén, B., Karlsson, M.O. et al. Population Pharmacokinetics of Melagatran, the Active Form of the Oral Direct Thrombin Inhibitor Ximelagatran, in Atrial Fibrillation Patients Receiving Long-Term Anticoagulation Therapy. Clin Pharmacokinet 45, 803–819 (2006). https://doi.org/10.2165/00003088-200645080-00004

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.2165/00003088-200645080-00004

Keywords

Search

Navigation